BSX · Earnings call · 2026Q3T · Full report

Urology and Endoscopy Trends

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 31 · Surprise 32

Urology declined 3% in Q3, affected by the cyber incident and expanding China pricing pressure; management said recent stone-product approvals and commercial-team stabilization should improve its growth profile during 2027. Endoscopy declined 1%, reflecting China VBP and cyber effects, although management described underlying performance as strong, led by Axios. It expects endoscopy to perform closer to mid-single-digit market growth until the China VBP impact is annualized in Q4 2027, with stronger results thereafter as pricing comparisons ease and launches contribute.

Key facts

• Boston Scientific expects Endoscopy and Urology to grow in the lower- to mid-single-digit range in 2027, with Neuro slightly higher.
• Boston Scientific expects Endoscopy and Urology to have stronger 2028 results after lapping significant China VBP pricing impacts in Q4 2027.
• Boston Scientific expects new stone launches and stabilization and productivity from its S&M commercial organization to improve urology growth over 2027.
• Boston Scientific expects endoscopy performance to be closer to mid-single-digit market growth until it annualizes China VBP impact in Q4 2027.